Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 1/20 | 0.35 |
| ▸ | F2RL1 | P55085 | 2/20 | 0.34 |
| ▸ | SUV39H2 | Q9H5I1 | 4/20 | 0.32 |
| ▸ | UGCG | Q16739 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.31 |
| ▸ | TXK | P42681 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29538543 | 1.00 | SPR (0.35) | SPRF2RL1SUV39H2UGCGRET | |
| SCHEMBL16377964 | 0.93 | SPR (0.34) | SPRSUV39H2RETIMPDH2 | |
| SCHEMBL16378004 | 0.92 | UGCG (0.33) | UGCGTXKJAK3BTK | |
| SCHEMBL16377963 | 0.91 | F2RL1 (0.35) | SPRF2RL1SUV39H2UGCGIMPDH2 | |
| SCHEMBL16377947 | 0.90 | UGCG (0.33) | UGCG | |
| SCHEMBL29538748 | 0.86 | — | — | |
| SCHEMBL17382135 | 0.86 | — | — | |
| SCHEMBL22626262 | 0.84 | SUV39H2 (0.30) | SUV39H2 | |
| SCHEMBL16377721 | 0.84 | UGCG (0.31) | UGCG | |
| SCHEMBL24519349 | 0.84 | SUV39H2 (0.30) | SUV39H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3157929-B1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | ARES TRADING SA (CH) | 2023-12-13 | — | — | EP | disclosed |
| US-20220402929-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | TOCOPHERX INC (US) | 2022-12-22 | — | — | US | disclosed |
| US-20220402929-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | TOCOPHERX INC (US) | 2022-12-22 | — | — | US | disclosed |
| US-11365199-B2 | Pyrazole compounds as modulators of FSHR and uses thereof | MERCK PATENT GMBH (DE) | 2022-06-21 | — | — | US | disclosed |
| CN-106573937-B | Pyrazole compounds as FSHR modulators and uses thereof | 阿瑞斯贸易股份公司 | 2022-02-11 | — | — | CN | disclosed |
| US-10941152-B2 | Pyrazole compounds as modulators of FSHR and uses thereof | ARES TRADING S.A. (CH) | 2021-03-09 | — | — | US | disclosed |
| US-10941152-B2 | Pyrazole compounds as modulators of FSHR and uses thereof | ARES TRADING S.A. (CH) | 2021-03-09 | — | — | US | disclosed |
| EP-3013832-B1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-11-04 | — | — | EP | disclosed |
| EP-3013832-B1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-11-04 | — | — | EP | disclosed |
| US-20190135823-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | TOCOPHERX, INC. | 2019-05-09 | — | — | US | disclosed |
| US-20190135823-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | TOCOPHERX, INC. | 2019-05-09 | — | — | US | disclosed |
| US-10208055-B2 | Pyrazole compounds as modulators of FSHR and uses thereof | TOCOPHERX, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10208055-B2 | Pyrazole compounds as modulators of FSHR and uses thereof | TOCOPHERX, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170253605-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | TOCOPHERX, INC. (US) | 2017-09-07 | — | — | US | disclosed |
| US-20170253605-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | TOCOPHERX, INC. (US) | 2017-09-07 | — | — | US | disclosed |
| US-20170253605-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | TOCOPHERX, INC. (US) | 2017-09-07 | — | — | US | disclosed |
| US-20160152626-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-06-02 | — | — | US | disclosed |
| US-20160152626-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-06-02 | — | — | US | disclosed |
| WO-2014209980-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | MERCK PATENT GMBH (DE) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208055-B2 | Pyrazole compounds as modulators of FSHR and uses thereof | FSHR, GNRHR, LHCGR | SPR 266/4885F2RL1 1177/4885SUV39H2 1545/4885 |
| US-11365199-B2 | Pyrazole compounds as modulators of FSHR and uses thereof | FSHR, GNRHR, LHCGR | SPR 227/4885F2RL1 774/4885SUV39H2 1345/4885 |
| US-20170253605-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | FSHR, GNRHR, LHCGR | SPR 266/4885F2RL1 1177/4885SUV39H2 1545/4885 |
| US-20190135823-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | FSHR, GNRHR, LHCGR | SPR 227/4885F2RL1 774/4885SUV39H2 1345/4885 |
| US-20220402929-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | FSHR, GNRHR, LHCGR | SPR 227/4885F2RL1 774/4885SUV39H2 1345/4885 |
| US-20160152626-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | FSHR, GNRHR, LHCGR | SPR 227/4885F2RL1 774/4885SUV39H2 1345/4885 |
| US-10941152-B2 | Pyrazole compounds as modulators of FSHR and uses thereof | FSHR, GNRHR, LHCGR | SPR 227/4885F2RL1 774/4885SUV39H2 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.